Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Ependymoma × Irinotecan × Clear all

Phase

Status

Completed 3 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 24 Pancreatic Neoplasms 11 Neuroblastoma 10 Stomach Neoplasms 8 Neoplasm Metastasis 8 Neoplasms 7 Rectal Neoplasms 5 Small Cell Lung Carcinoma 3 Esophageal Squamous Cell Carcinoma 3 Colonic Neoplasms 3 Breast Neoplasms 3 Adenocarcinoma Of Esophagus 3 Wilms Tumor 2 Sarcoma, Ewing 2 Rhabdomyosarcoma 2 Recurrence 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Ovarian Neoplasms 2 Osteosarcoma 2 Esophageal Neoplasms 2 Endometrial Neoplasms 2 Biliary Tract Neoplasms 2 Advanced Solid Tumors 2 Adenocarcinoma 2 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Prostatic Neoplasms 1 Pediatric Solid Tumor 1 Pathologic Complete Response 1 Pancreatic Ductal Adenocarcinoma 1

Interventions

Temozolomide 2 ONC206 2 Etoposide 2 Cyclophosphamide 2 lutetium Lu 177 dotatate 1 ibrutinib 1 fenofibric acid 1 etoposide phosphate 1 Thalidomide 1 Restraint, Physical 1 Radiotherapy 1 Radiation 1 Magnetic Resonance Spectroscopy 1 Linear Energy Transfer 1 Irinotecan 1 Elasticity Imaging Techniques 1 Cytarabine 1 Celecoxib 1 Bevacizumab 1 Automobiles 1 1-methyltryptophan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01356290 2026-02-23

MEMMAT

Medical University of Vienna

Phase 2 Recruiting

Ependymoma, Medulloblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡